DAPA-MEMRI試験 (DAPA-MEMRI)
心不全患者の心筋カルシウム処理に対するダパグリフロジンの効果を評価するための観察的断面研究および二重盲検プラセボ対照無作為対照試験 - DAPA-MEMRI試験。
Diabetes mellitus is among the top 10 causes of death worldwide with an increasing incidence. Patients with diabetes are at risk of developing heart failure which is characterised by significant changes in the heart muscle including scarring and thickening. Contraction of the heart involves movement of calcium across the heart muscle and disruption of this process is an early change seen in heart failure. Recently, a drug therapy (SGLT2 inhibitor therapy) in patients with diabetes was shown to benefit patients with heart failure but the mechanisms of benefit are unknown.
Our hypothesis is that calcium handling is altered in patients with either type 2 diabetes mellitus (T2DM) or heart failure and that SGLT2 inhibitors can improve this in heart failure irrespective of the presence of T2DM.
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function by using a new contrast 'dye' containing manganese that has shown advantages over traditional contrast. We plan to further test this new dye as it has the potential to track and quantify improvements in heart function over time and detect changes in calcium handling in the heart muscle, making it an ideal measure to identify the mechanisms of benefit from SGLT2 inhibitor therapy.
The study population will comprise patients with heart failure with and without type 2 diabetes, patients with type 2 diabetes without heart failure and healthy volunteers. Baseline comparisons will be made between the four groups before progressing to the randomised controlled trial with heart failure patients only. Patients will have a clinical assessment and blood tests, electrocardiogram, echocardiogram and MRI of the heart at each visit.
If successful, this study will give us significant insights into mechanisms of action of SGLT2 inhibitors in heart failure and will enable us to tailor specific treatments in heart failure patients.
調査の概要
詳細な説明
The study is designed to investigate the myocardial calcium handling in patients with heart failure with or without type 2 diabetes mellitus and if Dapagliflozin (study drug) improves the myocardial calcium handling in patients with heart failure and diabetes mellitus.
We propose to conduct this study in two parts.
-
OBSERVATIONAL CROSS-SECTIONAL STUDY
An observational cross-sectional study will be undertaken to compare myocardial calcium in patients with diabetes mellitus and normal left ventricular ejection fraction (n=20), patients with heart failure in the absence of diabetes mellitus (n=60), and patients with both diabetes mellitus and heart failure (n=60). They will be compared with healthy volunteers (n=20).
There will be an initial meeting, where informed consent will be documented and a medical assessment including blood tests will be undertaken as well as an echocardiogram will be performed. Healthy volunteers will only undergo Manganese enhanced cardiac MRI scan. The other cohorts will undergo a gadolinium enhanced cardiac MRI scan on their first visit. On a subsequent visit, they will undergo 1 cardiac Manganese enhanced Manganese MRI scan (MEMRI) which lasts 45-60 minutes. Participants will be monitored with blood pressure and ECG monitoring throughout the MEMRI scan. Patients will be offered an anti-sickness medication if required following the MEMRI scan.
-
RANDOMISED CONTROLLED TRIAL
We will undertake a randomised double-blind placebo controlled trial of patients with heart failure with (n=60) and without (n=60) type 2 diabetes mellitus. These participants would have been recruited as part of the observational study as described above from out-patient clinics at the Edinburgh Heart Centre. If all eligibility criteria are met, patients will be randomised to receive treatment with either Dapagliflozin 10 mg, or matched placebo, once daily for 6 months at a ratio of 1:1. Detailed clinical assessment including history and examination, blood sampling, electrocardiogram, echocardiogram and cardiac MRI will be collected at baseline, 1 and 6 months.
There will also be a 3 month safety visit after randomisation to record any adverse events.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Scotland
-
Edinburgh、Scotland、イギリス
- University of Edinburgh
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patients with heart failure (with or without type 2 diabetes mellitus)
- Aged over 18 years
- Diagnosis of symptomatic reduced ejection fraction heart failure for at least 2 months
- Left ventricular ejection fraction ≤40%
- Elevated N-terminal pro B-type natriuretic peptide (>125 pg/mL)
- Clinical diagnosis of type 2 diabetes mellitus for 50% of patient population - on stable therapy for at least 12 months or more.
Patients with Type 2 Diabetes Mellitus and no heart failure
-
Aged over 18 years
-
Clinical diagnosis of type 2 diabetes mellitus (diagnosed by either HbA1c of 48mmol/mol (6.5%) or greater or fasting plasma glucose level of 7mmol/L or greater at the time of diagnosis)
- on stable therapy for at least 12 months or more.
-
Normal left ventricular systolic ejection fraction
Healthy Volunteers
- Aged over 18 years
- Normal left ventricular ejection fraction and glycaemia
- No clinically significant co-morbid conditions
Exclusion Criteria:
Patients with heart failure (with or without type 2 diabetes mellitus)
- Receiving an SGLT2 inhibitor within 8 weeks of enrolment
- Previous intolerance of, or contraindication to, an SGLT2 inhibitor
- Standard magnetic resonance imaging safety exclusions
- Severe renal impairment (eGFR <30millilitre/min. 1.73m2)
- Type 1 diabetes mellitus
- Symptomatic hypotension or systolic blood pressure <95 mmHg
- Recent (within 12 weeks) hospitalisation for heart failure, acute cardiovascular event (such as myocardial infarction or stroke) or coronary re-vascularisation.
- 2nd or 3rd degree atrioventricular block Atrial fibrillation or flutter with poor ventricular rate control (>100 /min)
- Heart failure due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease
- New York Heart Association grade IV heart failure
- Obstructive liver function testing abnormalities
- Concomitant digoxin, diltiazem or verapamil therapy.
Patients with type 2 diabetes mellitus and no heart failure
- Other major clinically significant co-morbid conditions
- History of ischaemic heart disease or present history suggestive of probable clinically significant underlying ischaemic heart disease
- Standard magnetic resonance imaging safety exclusions
- Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2)
- Receiving a SGLT2 inhibitor at any time
- Symptomatic hypotension or systolic blood pressure <95 mmHg
- Abnormal electrocardiogram
- Clinically significant abnormalities of clinical haematology or biochemistry measurements.
Healthy Volunteers
- Major or clinically significant cardiovascular disease
- Diabetes mellitus
- Receiving an SGLT2 inhibitor at any time
- Standard magnetic resonance imaging safety exclusions
- Moderate or severe renal impairment (eGFR <45 mL/min. 1.73m2)
- Symptomatic hypotension or systolic blood pressure <95 mmHg
- Abnormal electrocardiogram
- Clinically significant abnormalities of clinical haematology or biochemistry measurements.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Patients with heart failure without type 2 diabetes
60 patients with heart failure without type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation. |
Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo. Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo. |
|
他の:Patients with heart failure with type 2 diabetes
60 patients with heart failure with type 2 diabetes will be recruited and will either be randomised to placebo or Dapagliflozin after their baseline cardiac MRIs. They will have 2 cardiac MRIs (gadolinium and manganese enhanced) at baseline and further manganese enhanced cardiac MRI at 1 month post randomisation + gadolinium and manganese enhanced cardiac MRI at 6 months post randomisation. |
Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo. Patients with heart failure with or without type 2 diabetes will be either randomised to 10mg Dapagliflozin once daily or matched placebo. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
マンガン増強心臓MRIによる心筋T1値の変化率
時間枠:6ヵ月
|
6ヵ月
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
心臓 MRI でパーセンテージで測定された左心室駆出率
時間枠:6ヵ月
|
6ヵ月
|
|
心臓 MRI でグラム単位で測定された左心室質量
時間枠:6ヵ月
|
6ヵ月
|
|
N末端プロB型ナトリウム利尿ペプチドなどの心臓バイオマーカー(ナノグラム/リットル)
時間枠:6ヵ月
|
6ヵ月
|
|
ミリモル/リットルのグルコースを含む糖尿病コントロールのマーカー
時間枠:6ヵ月
|
6ヵ月
|
|
心拍数/分などの臨床的測定
時間枠:6ヵ月
|
6ヵ月
|
|
心臓MRI測定によるパーセンテージでの細胞外容積
時間枠:6ヵ月
|
6ヵ月
|
|
心臓 MRI で計算された全体的な縦ひずみのパーセンテージ
時間枠:6ヵ月
|
6ヵ月
|
|
キログラム単位の体重などの臨床的測定
時間枠:6ヵ月
|
6ヵ月
|
|
水銀柱ミリメートル単位の血圧などの臨床的測定
時間枠:6ヵ月
|
6ヵ月
|
|
高感度心筋トロポニン I などの心臓バイオマーカー (ナノグラム/リットル)
時間枠:6ヵ月
|
6ヵ月
|
|
糖化ヘモグロビン (HbA1c) などのグルコース制御の尺度 (ミリモル/モル)
時間枠:6ヵ月
|
6ヵ月
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。